FDA Clearance Tracker · P100020
COBAS HPV TEST
Last checked: Nov 20, 2026Latest source record: Apr 19, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Apr 19, 2011
Approved
Time to decision
322 days
Received Jun 1, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P100020
- Device name
- COBAS HPV TEST
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Jun 1, 2010
- Decided
- Apr 19, 2011
- Decision
- Approved
- Supplements
- 65 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE COBAS HPV TEST. COBAS HPV TEST INDICATIONS FOR USE: THE COBAS HPV TEST IS A QUALITATIVE IN VITRO TEST FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) IN PATIENT SPECIMENS. THE TEST UTILIZES AMPLIFICATION OF TARGET DNA BY THE POLYMERASE CHAIN REACTION (PCR) AND NUCLEIC ACID HYBRIDIZATION FOR THE DETECTION OF 14 HIGH-RISK (HR) HPV TYPES IN A SINGLE ANALYSIS. THE TEST SPECIFICALLY IDENTIFIES TYPES HPV 16 AND HPV 18 WHILE CONCURRENTLY DETECTING THE REST OF THE REST OF THE HIGH RISK TYPES (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 AND 68). THE COBAS HPV TEST IS INDICATED: 1) TO SCREEN PATIENTS 21 YEARS AND OLDER WITH ASC-US (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) CERVICAL CYTOLOGY TEST RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY; AND 2) TO BE USED IN PATIENTS 21 YEARS AND OLDER WITH ASC-US CERVICAL CYTOLOGY RESULTS, TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY; 3) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED WITH CERVICAL CYTOLOGY TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT; AND 4) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED TO ASSESS THE PRESENCE OR ABSENCE OF HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT....(SEE APPROVAL ORDER FOR ADDITIONAL APPROVAL STATEMENT DETAIL).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MAQ. The earliest in FDA's data is P880009, decided Dec 23, 1988.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.